Category Archives: Cell Therapy

Dennis James roundtables on The Menace Podcast have features some serious star power, but none may be bigger than the eight-time Mr. Olympia, Ronnie Coleman, who joined DJ, Milos Sarcev, and Chris Cormier on the Sept. 25 episode.

In the beginning of the discussion, James asked Coleman about his stem cell treatments. After numerous surgeries, Coleman had been dealing with a lot of pain. However, his treatments had made a huge difference in the right way. He told the panel that pain is no longer an issue.

I have to keep going, though, thats the only thing. Ive had five treatments so far, Coleman said. They have cut my pain medications in half.

James eventually brought up the 2022 Mr. Olympia, and mentioned that when Coleman made predictions about contests, he was usually right. When asked about new talent coming in and placing high, Coleman predicted that the top three will remain the same as it did in 2021, referencing defending two-time winner Big Ramy, 2019 winner Brandon Curry, and 2021 Peoples Champion Hadi Choopan.

I see the same guys in the same top three, Coleman prophesized. Andrew [Jacked], Nick, and maybe the 212 guy, [Derek] Lunsford, can crack the top five. I dont see any of them making it in the top three, though.

James also suggested that some people feel this years Olympia may be the best ever. The eight-time Mr. Olympia agreed with Sarcev that 1999 may go down as the most memorable contest ever.

Me, Flex [Wheeler], Kevin [Levrone}, Chris [Cormier], and Nasser [El Sonbaty] were there, and everybody was in good shape and good condition back then.

The panel also discussed Colemans career in detail going back to his amateur days, his frequent traveling and popularity in spite of not competing in 15 years, and much more. Subscribe to the Muscle & Fitness YouTube channel to see this episode of TMP in its entirety, and subscribe so you can see more episodes as well as other great content. New episodes of TMP drop every Sunday at 3 PM Eastern time.

Visit link:
Ronnie Coleman Says He's Nearly Pain Free Thanks to Stem Cell Therapy - Muscle & Fitness

Personalized treatment for advanced melanoma using tumor-infiltrating lymphocytes (TILs)T cells with a proven ability to recognize and fight cancerreduced the risk of disease progression or death compared with checkpoint inhibitor immunotherapy, according to research presented at the European Society for Medical Oncology (ESMO) Congress 2022.

This study shows for the first time in a randomized, controlled trial that cell therapy can be efficacious and beneficial for patients with solid cancers, lead investigator John Haanen, MD, of the Netherlands Cancer Institute in Amsterdam, said in an ESMO press release. For patients with melanoma, we see a 50% reduction in the chance of progression of the disease or dying from the disease, which is absolutely practice changing.

Melanoma is among the malignancies most susceptible to immunotherapy, treatment that helps the immune system fight cancer. Standard therapy for advanced melanoma may include the PD-1 checkpoint inhibitors Keytruda (pembrolizumab) or Opdivo (nivolumab), which restore T-cell activity against cancer cells, or the CTLA-4 inhibitor Yervoy (ipilimumab), which promotes T-cell proliferation.

Tumor-infiltrating lymphocyte therapy is a customized treatment that involves collecting T cells from a patients tumor sample, multiplying them in a laboratory and reinfusing the expanded cells back into the body. TIL therapy is not newit was developed at the National Cancer Institute in the 1980sbut while some patients had very good outcomes, the side effects could be severe, and it took a backseat to checkpoint inhibitor immunotherapy.

The Phase III M14TIL trial compared TIL therapy versus Yervoy in 168 adults with previously treated unresectable (inoperable) Stage IIIC to Stage IV melanoma, nearly 90% of whom had progressed despite treatment with a PD-1 inhibitor. This is the first randomized, controlled trial to compare TIL therapy against a checkpoint inhibitor.

[Checkpoint inhibitors] have a very good safety profile and quite high efficacy and are now often given as first-line therapy, Haanen said. But if patients fail first-line treatments, then the options become very scarce, particularly for patients failing anti-PD-1 drugs, so there is a real unmet need.

The participants were randomly assigned to receive a single round of TIL therapy or up to four doses of Yervoy administered by IV infusion every three weeks. Those assigned to the TIL group were hospitalized and underwent strong chemotherapy to reduce the number of existing lymphocytes and make room for the new ones. After the cell infusion, they received high doses of interleukin-2, a cytokine that stimulates T-cell growth and activity.

People treated with TIL therapy had significantly longer progression-free survival (PFS), meaning they were still alive without disease progression. The median PFS time was 7.2 months with TIL therapy versus 3.1 months with Yervoy, and the PFS rates at six months were 53% versus 21%, respectively. Overall survival also appeared to be longer in the TIL group (25.8 months versus 18.9 months), but follow-up is ongoing. The overall response rate, or tumor shrinkage, was more than twice as high in the TIL group (49% versus 21%), and the complete response rate, or full remission, was nearly three times as high (20% versus 7%).

TIL treatment was generally safe, but side effects were common. Everyone who received TIL therapy and 57% of those treated with Yervoy experienced Grade 3 or higher adverse events. Common side effects included white blood cell and platelet deficiencies, which can lead to infections and excessive bleeding. Most of the adverse events were attributable to the accompanying chemotherapy or interleukin-2 rather than the TILs themselves. However, Haanen noted, these side effects are well manageable and most resolve by the time patients leave the hospital after their TIL therapy.

Speculating about why TIL therapy is effective after PD-1 checkpoint inhibitors have stopped working, Haanen said, We think that the mechanism of resistance to anti-PD-1 treatment is mostly delivered by the tumor microenvironment. So when we take these cells out of their natural environment, reactivate them in the laboratory, grow them up to very large numbers and give them back to the patients, we can overcome some of the escape mechanisms.

Haanen added that TIL therapy has the potential to work against a wide variety of solid tumors, and clinical trials are currently underway for people with many malignancies, including lung, cervical and head and neck cancers.

However, the process is labor-intensive and expensive, which could limit its commercial potential. This study was conducted by academic researchers in the Netherlands and Denmark without pharmaceutical industry involvement. The Netherlands government has agreed to use TIL therapy, and the researchers are seeking approval from the European Medicines Agency. In the United States, the Food and Drug Administration has strict requirements for cell-based therapies, and it may be difficult to win approval without industry support for specific products. That was the path taken by CAR-T therapy, which modifies a patients T cells to make them better cancer fighters rather than relying on naturally occurring immune cells.

Click here to read the study abstract.Click here formore reports from ESMO 2022.Click here to learn more about immunotherapy for cancer.

Read more from the original source:
T-Cell Therapy Delays Disease Progression for People With Advanced Melanoma - Cancer Health Treatment News

Osteoarthritis (OA) is a slowly progressive joint disease that is a major cause of disability and pain among the elderly, second only to cardiovascular disease. The OA space is characterised by a high level of unmet clinical need driven by the limited effectiveness of currently available analgesics and the lack of disease-modifying OA drugs (DMOADs). The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and intra-articular injections. As such, key opinion leaders (KOLs) interviewed by GlobalData strongly believe that the development of DMOADs is the greatest current unmet need in the OA space.

Increased research into OA over the past decade has led to the identification of new targets, and this progress is reflected in the current OA pipeline. Cell-based therapies have the potential to address this unmet need within the OA space to some degree. Within the OA late-stage pipeline, there are two cell-based therapies that GlobalData believes have significant clinical and commercial potential. These are TissueGenes Invossa and Organogenesis Holdings ReNu, both of which have shown disease-modifying efficacy in clinical trials. Invossa has demonstrated the efficacy and safety of a single shot for up to three years, as outlined by Lew in a 2019 study published in Osteoarthritis and Cartilage (NCT03383471). Similarly, ReNu also showed positive efficacy and safety for up to 12 months from a single intra-articular injection (NCT02318511, NCT03063099).

Commercially, these therapies have the potential to be first-in-class DMOADs and to establish a novel paradigm in OA treatment and management. According to GlobalDatas primary research, while GlobalData initially expects a slow uptake for such cell-based therapies due to their high price, as they will require some time to prove their cost-effectiveness, the uptake is likely to improve following the initial lag period as physicians become accustomed to the therapy and as their cost-effectiveness becomes more apparent. Furthermore, the high price associated with these biologics may lead to reimbursement barriers in the genericised OA market, especially in the five major European markets (5EU: France, Germany, Italy, Spain and the UK), where a greater emphasis is placed on drug pricing and cost-effectiveness compared with the US.

However, even with the entry of cell therapies to the market, the unmet need for improved analgesics will likely continue to be largely unfulfilled, and an abundance of opportunities for the development of novel analgesics and additional DMOADs will remain. OA is considered to be a heterogeneous disease with a complicated pathophysiology and unclear aetiology. As such, distinct OA patient populations exist, and therapies targeting these subgroups are needed. Moreover, OA is most prevalent in elderly patients who often have other comorbid conditions, such as diabetes or hypertension, but the currently available treatment modalities for OA are often contraindicated in these patients. Therefore, one of the remaining unmet needs in this disease area is for therapies that address OA and are appropriate to use despite the comorbidities an elderly patient may have.

Overall, considering the novel analgesics and DMOADs in the OA pipeline, GlobalData expects the OA treatment algorithm to change significantly in the future, with cell therapies garnering significant market share during the next decade.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows thehighest standardsof journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Consent and Preference Management Solution for Healthcare Providers

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the products developer.This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

More:
Cell-based therapies set to become major players in the osteoarthritis market - Pharmaceutical Technology

HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced early clinical data from the first patient in its ongoing TCR-T Library Phase 1/2 trial. The data will be presented during a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 through October 1, 2022.

The encouraging data from the first patient in our trial highlight the potential of our non-viral TCR-T cell therapies to treat solid tumors even at the lowest doses in the study design, said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. Patients with solid tumors represents a large unmet medical need, and the results from the first patient are quite promising that our TCR-T cell therapy may offer them hope. We look forward to treating additional patients and are grateful for the continued support from our investigators, patients and our dedicated team.

Marcelo V. Negrao, MD, Department of Thoracic/Head & Neck Med Onc, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center added, These clinical data, where a greater than 51% tumor regression in a patient with NSCLC was observed, are encouraging. We believe this data adds to the growing body of evidence indicating that targeting shared tumor-specific hotspot mutations using TCRs has the potential to transform the way we treat solid tumor cancers. In addition, we believe that the manageable safety and tolerability profile is reassuring, and we look forward to continuing enrollment in the study.

The TCR-T Library Phase 1/2 trial is an open label, dose escalation study being conducted at MD Anderson. The trial is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers that have a matching human leukocyte antigen (HLA) and hotspot mutation pairing in Alaunos TCR-T library.

Key highlights to be presented:

Details of the presentation are as follows:

Title: Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced non-small cell lung cancerPresenter: Marcelo V. Negrao, MD, Department of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine at MD AndersonDate and Time: Friday, September 30, 2022, 9:00-9:15am ETSession Title: Session 6: Cellular Therapies: Engineering T cells

The full abstract may be accessed by visiting http://www.cancerimmunotherapyconference.org.

About Alaunos TherapeuticsAlaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has a clinical and strategic collaboration with the National Cancer Institute. For more information, please visit http://www.alaunos.com.

Forward-Looking Statements Disclaimer This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as may, will, could, expects, plans, anticipates, believes or other words or terms of similar meaning. These statements include, but are not limited to, statements regarding the Company's business and strategic plans, the anticipated outcome of preclinical and clinical studies by the Company or its third-party collaborators, the Companys manufacturing capabilities and the timing of the Company's research and development programs, including the expected timeline for enrolling and dosing patients and the timing and forums for announcing data from the Company's clinical trials. Although the management team of Alaunos believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Alaunos, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, changes in the Companys operating plans that may impact its cash expenditures; the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Alaunos product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Alaunos intellectual property rights; and competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Alaunos, including those risks and uncertainties listed in the most recent periodic report filed by Alaunos with the Securities and Exchange Commission. Alaunos is providing this information as of the date of this press release, and Alaunos does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

Investor Relations Contact:Alex LoboStern Investor Relationsalex.lobo@sternir.com

1 Cyclophosphamide (60 mg/kg for 2 days) and Fludarabine (25 mg/m2 for 5 days)

See original here:
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference -...

Boasting an outstanding safety record, lentiviral vectors (LVV) are key components in CAR-T cell therapy manufacturing. Unfortunately, owing to the lack of a robust and scalable production platform, therapy providers too often experience highly variable quality, inconsistent yields, and poor recoveries, leading to severe disruptions in the supply chain, said the partners.

By combining Cellares automation and robotics technology with iVexSols viral vector expertise, the two entities aim to develop consistent, high-quality solutions for viral vector manufacturing to improve access to this critical reagent.

iVexSol will supply Cellares with high-quality LVV to support the development of its automated, closed, end-to-end cell therapy manufacturing platform, the Cell Shuttle with an eye on leveraging that technology to automate the entire manufacturing process, including vector production.

While Cellares primary focus has always been cell therapy manufacturing, it said it intentionally developed its Cell Shuttle in a manner that provides flexibility in the processes and technologies that it can support. The platform can be easily adjusted to different customer processing needs and supports a variety of cell therapy modalities.

That company's CEO, Fabian Gerlinghaus, told BioPharma-Reporter: "Both Cellares and iVexSol are focused on creating access to cell therapies. In addition to the actual cell therapy manufacturing bottleneck, we also need to solve the viral vector manufacturing bottleneck. We're working with iVexSol to explore how our automated and flexible bioprocessing technologies can be leveraged to create optimized solutions for viral vector manufacturing. This is a natural fit for our technology since the flexibility to support different bioprocessing workflows has been a central pillar of our architecture from the beginning."

Financial terms of the agreement have not been disclosed.

We spoke to Gerlinghaus back in May where he outlined why automation is key to making cell therapy manufacturing a viable industry.

Read this article:
Solving CAR-T's viral vector problem: Cellares and iVexSol team up to streamline manufacturing - BioPharma-Reporter.com

FatCamera/Getty Images

The concept of therapeutic cancer vaccines emerged in the late 1980s but, some 35 years later, it still hasnt resulted in an approved product. The advances in immuno-oncology and adaptive cell therapy that began about a decade ago, however, are enabling fresh, biology-driven approaches with the potential to bring therapeutic cancer vaccines much closer to fruition.

One challenge has been the question of how to elicit an immune response to a tumor, which is a mutated part of the self rather than a foreign entity.

Another problem is that tumors from different sites in the body have different mutations, said Muhammad Al-Hajj, Ph.D., CSO at IO Biotech in an interview with BioSpace. So, while a specific cancer vaccine might work against one tumor, it wont wipe out all the tumor cells throughout the body.

A third hurdle is that tumors protect themselves with a shield of normal cells. For example, Al-Hajj said, In breast cancer, the percentage of actual tumor cells within the mass is less than 50 percent. In pancreatic tumors, 90 percent of the cells are non-cancerous. Thats why pancreatic cancer is so difficult to treat. It brings a whole network of normal cells, that help protect the cancerous cells from the immune system. Therefore, You need something that could wipe out most or all of the cancer cells, he explained.

Boosting the Potential of Immuno-oncology

Checkpoint inhibitors, a leading immuno-oncology strategy, arent effective for all patients. They also have multiple toxicities when combined with other agents.

IO Biotech has a technology platform, called T-win, that activates T cells to directly kill immunosuppressive cells and gently modulate the tumor microenvironment to be less receptive to tumors. Its lead candidate, IO102/IO103, targets the indoleamine 2,3-dioxygenase (IDO) enzyme and programmed death ligand 1 (PD-L1).

Whats particularly novel is that rather than just targeting the cancer cells within the tumor, IO Biotech is developing a vaccine against the key elements within the tumor that pushes the T cells away.

Vaccination modulates the environment in a way that is very gentle and non-toxic, Al-Hajj said. This is not a standard vaccine. Its a vaccine for tumor microenvironment targets. The idea is to modulate the tumor microenvironment and to combine (the vaccine) with a very powerful immune therapylike a checkpoint inhibitorto allow them to infiltrate better.

A Phase I/II trial of 30 melanoma patients showed that vaccination elicited a response in about 80 percent of the patients, whereas a checkpoint inhibitor elicited a response in slightly less than 50 percent.

Biomarker analysis proved the cells start to infiltrate the tumor. Now we are working to prove it in a much larger trial, Al-Hajj shared. Additional clinical trials are underway in first-line solid tumors and as a neo-adjuvant/adjuvant for solid tumors for lung, head & neck and bladder cancers. The vaccine holds FDA breakthrough designation.

There are, of course, many different approaches to therapeutic cancer vaccines.

Targeting the Lymph Nodes

Elicio Therapeutics is targeting the lymph nodes - which the company calls the brain center of the immune system - with its Amphiphile (AMP) platform.

The role the lymph nodes play in organizing the immune response has been known for a very long time, said Pete DeMuth, Ph.D., CSO at Elicio. But, I think we just assumed that after injection, everything sort of went there eventually so it didnt need a lot of intentional design consideration.

Over time, though, scientists discovered there actually were very large differences in the way injected agents distribute throughout the body, DeMuth told BioSpace. Now were starting to see an emphasis on lymph node targeting because we understand enough about the underlying biology to design technologies that allow us to optimize lymph node delivery.

One of the first challenges in this approach is to design molecules of the optimal size to reach the lymph nodes.

Molecules that are too large or too small wont get there very well, DeMuth said. Then, once the molecules arrive, they must be delivered to the right cells within the lymph nodes.

So, Elicio founder and MIT professor Darrell Irvine, Ph.D., designed AMP to direct drugs or other payloads to the lymph nodes. His approach leveraged engineering, material science and biology.

We modify a vaccine molecule by linking a lipid to it to teach the immune system how to collect it and use it as information to develop a response that will protect against cancer, DeMuth explained. The lipid allows the vaccine to bind to albumin (a protein in the tissue), which acts as a shuttle bus to transport things from the tissue into the lymph nodes. The AMP is like the bus pass that allows these agents to get on the shuttle bus.

This system can be applied to many different vaccine or drug agents, including possibly drugs that were limited in their activity because they couldnt reach the immune cells or because they went to other places in the body and caused toxicities, he suggested.

By giving them this AMP modification, (they go) straight into the lymph nodes where they can modulate the biology of the immune cells and simultaneously reduce their exposure to other sites in the body that might drive safety concerns or have toxicities that would limit their usefulness.

The AMP system is currently undergoing a Phase I trial to treat mutant KRAS-driven cancers in the gastrointestinal tract or lungs. Early results havent been released, but DeMuth says he is very optimistic given our preclinical results and the history around this type of therapy.

Going After Cancer Cells Survival Mechanism

In another advance, IMV Inc. recently announced positive data in metastatic bladder cancer patients using its cancer vaccine, Maveropepimut-S (MVP-S) also known as DPX-Survivac.

It shows complete responses, even in patients who had already progressed through immune checkpoint inhibitors. Response are beyond 600 or 700 days and are still ongoing, said Jeremy Graff, Ph.D., CSO, in an interview with BioSpace.

What makes MVP-S unique among cancer vaccines is that its designed to instigate an immune response to a very common cancer protein called survivin, Graff said. Survivin is a protein that many cancers up-regulate during progression. As the name implies, it actually enables the survival of cancer cells.

What distinguishes MVP-S from prior cancer vaccines, Graff explained, is that we not only put the information into our therapeutic to provide a specific survivin signal, but we also put information to instigate the functionality of antigen-presenting cells (APCs) as well as CD4 T cells. This approach encapsulates multiple pieces of instruction that drive an immune response.

The duration of response for survivin-specific T cell activation exceeds two years. Duration is particularly important. CAR T cells often dont persist even though we put billions of cells into patients, Graff noted.

Data released from a Phase IIa study in summer 2021 showed durable responses among ovarian cancer patients that extended progression-free survival to about 20 months in nearly half the patients (who had already been exposed to multiple chemotherapies) who were treated with MVP-S. This was compared to about 10 to 12 months for those treated with chemotherapy.

A new trial has been submitted to the FDA and Health Canada to assess the clinical benefit for MVP-S and low-dose intermittent cyclophosphamide in platinum-resistant ovarian cancer patients.

More here:
Cancer Vaccines Push Toward Viability with New Approaches and Targets - BioSpace

SAN DIEGO & SINGAPORE--(BUSINESS WIRE)--ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics today announced that it has raised $14M in new financing. Existing investor Anzu Partners led the round with participation from new investor Amgen Ventures and Singapore-based global investor EDBI.

ImmunoScapes differentiated Deep Immunomics platform utilizes the companys proprietary combinatorial barcoding technology to enable the discovery and in-depth characterization of rare cancer-specific T-cells at high resolution. ImmunoScapes platform is able to simultaneously evaluate tens of millions of T-cells in blood samples from hundreds of cancer patients to identify rare clinically relevant T-cell clones. The corresponding TCRs are then evaluated and prioritized to build a diverse portfolio of TCR-T-cell therapies.

By leveraging computational biology and machine learning, together with high throughput screening and evaluation of T-cell clones, ImmunoScape is able to efficiently identify novel T-cell therapy targets and TCR candidates. ImmunoScape has extensively validated its computational platform using virus-specific T-cells and is applying the same methods to build an extensive portfolio of cancer-specific TCRs.

We have made significant strides in our discovery program and have identified several compelling clinical TCR candidates using our Deep Immunomics platform, said Choon Peng Ng, CEO, ImmunoScape. The new funding will allow us to expedite our development efforts and help us to advance our therapeutic candidates toward the clinic. We are especially delighted that Amgen Ventures has become an investor and we look forward to working with their team to address important unmet medical needs with ImmunoScapes technology.

Amgen invests in promising new solutions to address healthcares biggest challenges, especially those that offer unique, value-based approaches that align with our mission to serve patients fighting serious illness, said Philip Tagari, vice president of research (therapeutic discovery), Amgen. ImmunoScapes Deep Immunomics and machine learning platforms have the potential to help uncover new treatments as we continue to develop the next generation of innovative medicines. We are excited to work with their team to unlock the full power of this technology.

With research laboratories in both San Diego and Singapore, ImmunoScape is one of the global pioneers of TCR discovery. Their unique high-throughput TCR discovery and evaluation platform has an unprecedented capacity to test millions of human T-cells against hundreds of cancer antigens, said David Michael, managing partner at Anzu Partners. From their origins at Singapores Agency for Science, Technology, and Research (A*Star), the companys global team of immunologists are pursuing major breakthroughs in TCR cell therapy. We are delighted to work more closely with Amgen on these important efforts.

To learn more about ImmunoScape, please visit https://immunoscape.com/.

About ImmunoScapeImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.

About Anzu PartnersAnzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, intellectual property, global connectivity, and operations. For more information, please visit https://anzupartners.com/.

About Amgen VenturesAmgen Ventures is Amgen's corporate venture capital fund, dedicated to investing in emerging companies and technologies to advance promising new medicines and solutions to healthcares biggest challenges. For more information, please visit https://amgenbd.com

About EDBIInvesting since 1991, EDBI is a Singapore-based global investor in select high growth technology sectors ranging from Information & Communication Technology (ICT), Emerging Technology (ET), Healthcare (HC) and promising Singapore SMEs in strategic industries. As a value creating investor, EDBI assists companies achieve their ambitious goals by leveraging our broad network, resources, and expertise. With our growth capital, EDBI supports companies seeking to expand in Asia and globally through Singapore. For more information, please visit https://www.edbi.com.

See the original post:
ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors - Business Wire

SubscribeBe the first with the news that moves the market

Prescient Therapeutics (PTX) has unveiled a novel adjuvant for enhancing cellular immunotherapy.

The CellPryme-A product was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTXs CAR-T cell therapy. This is used to address the hostile tumour microenvironment that cellular immunotherapies face.

CellPryme-A can be administered either before or alongside cellular immunotherapy.

Prescient said in animal models, CellPryme-A had been shown to reduce the number of suppressive regulatory T cells surrounding solid tumours that counteracted the effectiveness of CAR-T and other cancer therapies.

While CellPrymeA demonstrated superior tumour killing and host survival in pre-clinical studies, its effects were even greater when used together with Prescients CAR-T manufacturing technology, CellPryme-M.

The company presented this new data at the seventh annual CAR-TCR Summit in Boston.

Prescient Managing Director and CEO Steven Yatomi-Clarke said the company was delighted to finally unveil CellPryme-A as a distinct but complementary addition to CellPryme-M.

Together with Prescients next-generation CAR platform, OmniCAR, Prescient has placed itself enviably at the forefront of cellular immunotherapy by creating technologies that overcome the challenges facing the field, Mr Yatomi-Clarke said.

The company said CellPryme-Awas now ready for clinical testing and could be incorporated into clinical studies of existing cell therapies.

Prescient Therapeutics was down 1.35 per cent and trading at 18 cents at 1:29 pm AEST.

Continue reading here:
Prescient Therapeutics (ASX:PTX) unveils new treatment to boost CAR-T performance - The Market Herald

Nizar Tannir, MD: Thank you, Scott, for sharing with us the data from the CLEAR study. I wanted to take this opportunity to ask Moshe [a question]. Moshe, youre familiar with the data, and you saw the data on the slides that Scott presented. In your mind, whats the rationale of combining lenvatinib with pembrolizumab? Is this impressive? The CR [complete response] rate was 16%, OR [overall response] was 71%, median PFS [progression-free survival] was 23.9 months, with a PFS hazard ratio of 0.39 and the OS [overall survival] benefit. Is that because lenvatinib is a potent VEGFR TKI [tyrosine kinase inhibitor]? Or do you think the fact that it also inhibits BFGF plays a role and produces these impressive results? Whats your take on that?

Moshe Ornstein, MD, MA: That was a great overview of the data. In some ways, were working backward. Of all the I/O [immuno-oncology]TKIs that have been approved, the CLEAR trial with lenvatinib and pembrolizumab was the last piece of the puzzle. That said, despite it being the last piece of the puzzle, it sets the bar and the new benchmark for what wed need to see to change the standard of care for treatment-nave metastatic clear cell RCC [renal cell carcinoma].

Getting to your question as to why those results were so impressive, Im not convinced that any single TKI is necessarily better or stronger based on the specific targets. Because theyre all VEGFR inhibitors, more important perhaps than the individual targets is the dosing. For the population at large, theres the concept of linear pharmacokinetics when it comes to VEGFR TKIs, such that collectively, a higher dose is generally equated with a higher plasma level and a better response. That said, there are some patients with very high doses whose cancers dont respond, and some patients on very low doses who have exceptional anti-tumor responses.

The No. 1 reason why the efficacy in this regimen was so impressivewith the I/OTKIs were looking at that up-front benefit of response rates and PFSis because they started at a high dose of lenvatinib at 20 mg and, as well see when we review the other I/OTKI regimens, there were different doses for the TKI. If you were to ask many kidney cancer specialists 3 or 4 years ago what data they would need to see from an I/OTKI regimen to have it set as a new benchmark, with numbers like a response rate of 70%-plus, a PFS of close to 2 years, and complete response rates of 16%, most would have said that numbers like that would at least make this combination extremely competitive in the growing landscape, if not set it apart as the optimal choice for the patient who can tolerate the toxicities and that dose of TKI.

Ill summarize by saying that these data are extremely impressive. They set a new benchmark for efficacy in the response rate, CR rate, and PFS components. I also think its related more to the dosing than it is to lenvatinibs different targets compared with some of the other TKIs.

Transcript edited for clarity.

See more here:
Rationale for Lenvatinib plus Pembrolizumab Therapy in Frontline Setting in Advanced Clear Cell RCC - Targeted Oncology

CAR T-cell therapy products will soon be available in Saudi Arabia, Singapore and Brazil, following the launch of Gilead and Kite Oncologys latest operations.

Commenting on the expansion into KSA, Eslam Khedr, Regional Business Unit Director for Cell Therapy and Oncology, Gilead and Kite Middle East said: Saudi Arabias Vision 2030 is a key reason Kite selected Saudi Arabia as the location of its first Middle East operation. We are establishing a fully functional oncology/cell therapy business unit in line with international best-in-class protocols with the aim of giving those with cancer the chance to be treated and to offer healthcare of an international standard.

Dedicated Gilead and Kite teams will work to qualify leading hospitals to administer CAR T-cell therapy in each of the new countries after local regulatory approvals. Plans are also in place to increase its workforce in these countries this year.

To date, Kite is the only company dedicated exclusively to the research, development, and manufacturing of cell therapy on a global scale. All its functions dedicated to this focus area are vertically integrated under one leadership team for efficient delivery of the highly specialised and complex end-to-end processes needed to support CAR T-cell therapy.

View original post here:
CAR T-Cell Therapy operations launched in Saudi Arabia - Omnia Health Insights